

From: Cathy Wright <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 1/10/2017 5:01:42 AM
Subject: RNA Therapeutics | Delving deeper into antisense technology and siRNA with AstraZeneca, Idera, Novartis and Quark

RNA Therapeutics 2017

8th Annual Conference: 22nd & 23rd February
Interactive Workshop: 21st February
Copthorne Tara Hotel, London, UK
Proudly Sponsored by: Lipocalyx

Get in touch for packages to **attend all 3 days**

[Register](#) | [Agenda](#) | [Website](#)

THIS WEEKS EVENT UPDATE:

Latest attendees confirmed from **Heptares Therapeutics**, **GSK**, **Mundipharma**, **ThermoFisher**, **Quark Pharmaceuticals**, **Exiqon**, **Roche**. [Sign up](#)

RNAi and RNA antisense technology dominates **global market** set to grow by 28.4% (CAGR between 2014-2020)

Conference showcase on antisense with detailed insight into siRNA presented by **AstraZeneca**, **Idera Pharmaceuticals**, **Novartis** and **Quark**. [Download brochure](#)

Dear Mr Tony Kester,

Due to its ability to render targeted solutions for a number of chronic and rare diseases, the global market for RNA based therapeutics is expected to create significant impact reaching \$1.2 billion by 2020, with enabled technologies such as RNA interference technology (RNAi) and RNA antisense technology dominating the market.*

Hear more on antisense technology and delve deeper into siRNA through four exciting keynotes in our industry showcase next month at [RNA Therapeutics 2017](#).

- **AstraZeneca** explain therapeutic antisense oligonucleotides in oncology with clinical updates on progress and methods in targeted drug delivery. Presented by Mark Edbrooke, Senior Principle Scientist.
- **Novartis Institute** for Biomedical Research reveal recent data on cell entry of exosomes as a novel paradigm for therapeutic RNA delivery providing clinical viability for siRNA therapy. Presented by Nicole Meisner-Kober, Senior Investigator, RNA Biology.
- **Idera discuss** antisense in the fourth decade with new insight into the design of 3GA, agonists and antagonists. Presented by Sudhir Agrawal, President of Research.
- **Quark Pharmaceuticals** explore siRNA to protect the kidney with detailed results from a large scale Phase II clinical trial. Presented by Shai Erlich, Chief Medical Officer and President USA.

[Visit the website](#) to see the full speaker line-up and detailed conference agenda.

3 KEY REASONS TO ATTEND

Will you be joining us in February? If you are still undecided, here are **3 key reasons to attend**:

1. CONTENT

This year's event will provide a comprehensive overview of current issues and ongoing considerations in RNA therapeutics, regulation and advancements in clinical trials to both new and established stakeholders. The packed agenda features:

- Over **17 thought provoking presentations** from industry thought leaders
- **Spotlight sessions** exploring drug formulation, gaining regulatory approval and enhancing drug delivery.
- Exclusive **MHRA** guidance on reporting clinical data.
- **Updates** from in both scientific research and clinical applications.
- New opportunities in cancer vaccines.

2. KEY PLAYERS ALL UNDER ONE ROOF:

With **3+ hours of networking**, RNA Therapeutics 2017 provides a perfect platform to build strategic partnerships and secure future collaborations. Confirmed attendee's include:

AstraZeneca | BioNTech AG | Carpmals & Ransford | Cydan | Diamond Biopharm | Exicure | Exiqon | GlobalAcorn | GSK | Heptares Therapeutics | Idera Pharmaceuticals | Imperial College London | Lipocalyx | MHRA | Mundipharma | Novartis | Quark Biotech | Roche GmbH | Roche Innovation Center Shanghai | Santaris Pharma | Silenseed | SilverRNA | ThermoFisher | University Of Twente | Valneva and more...

[Add your name to the list](#)

3. INTERACTIVE WORKSHOP

Don't forget to check out the [pre-conference interactive workshop](#) on Tuesday 21st February 2017 which has been carefully selected to bring you hands on training and complement the topics covered in the conference agenda.

Precision Nano-therapeutics: Minding the gap in delivery from preclinical studies to clinical success

08.30 – 12.30 | Hosted by Professor Andrew David Miller, Professor of Organic Chemistry & Chemical Biology, CSO, King's College London, KP Therapeutics Ltd

GET INVOLVED

Register your place at www.therapeutics-rna.com

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For delegate enquiries contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk

If you are unable to attend, please extend this invite onto your peers. We look forward to welcoming you when doors open next month at what is shaping up to be another successful show.

Kind Regards,

The SMi Pharmaceutical Team

www.therapeutics-rna.com

*Source: <http://bit.ly/2iuUGCR>

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>